Salvage Therapy for Hodgkin’s Lymphoma: A Review of Current Regimens and Outcomes

References

• Josting A, Müller H, Borchmann P, et al. Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin’s Lymphoma. J Clin Oncol. 2010;28(34):5074–5080. doi:10.1200/JCO.2010.30.577120975066
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Matasar MJ, Zelenetz AD, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non–cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood. 2012;119(7):1665–1670. doi:10.1182/blood-2011-10-38805822184409
   PubMed Web of Science ®Google Scholar
• Bröckelmann PJ, Müller H, Casasnovas O, et al. Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma. Ann Oncol. 2017;28(6):1352–1358. doi:10.1093/annonc/mdx07228327958
   PubMed Web of Science ®Google Scholar
• Adams HJA, Kwee TC. Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis. Ann Hematol. 2016;95(5):695–706. doi:10.1007/s00277-016-2619-926931115
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Nimer SD, Zelenetz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97(3):616–623. doi:10.1182/blood.V97.3.61611157476
   PubMed Web of Science ®Google Scholar
• Baetz T, Belch A, Couban S, et al. Gemcitabine, dexamethasone and cisplatin is an active andnon-toxic chemotherapy regimen in relapsed or refractory Hodgkin’s disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol. 2003;14(12):1762–1767. doi:10.1093/annonc/mdg49614630682
   PubMed Web of Science ®Google Scholar
• Josting A, Rudolph C, Reiser M, et al. Time-intensified dexamethasone/cisplatin/cytarabine:an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin’s disease. Ann Oncol. 2002;13(10):1628–1635. doi:10.1093/annonc/mdf22112377653
   PubMed Web of Science ®Google Scholar
• Rodriguez J, Rodriguez MA, Fayad L, et al. ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin’s disease. Blood. 1999;93(11):3632–3636. doi:10.1182/blood.V93.11.363210339468
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Niedzwiecki D, Johnson JL, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin’s lymphoma: CALGB 59804. Ann Oncol. 2007;18(6):1071–1079. doi:10.1093/annonc/mdm09017426059
   PubMed Web of Science ®Google Scholar
• Santoro A, Magagnoli M, Spina M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma. Haematologica. 2007;92(1):35–41. doi:10.3324/haematol.1066117229633
   PubMed Web of Science ®Google Scholar
• Santoro A, Mazza R, Pulsoni A, et al. Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: final Results of a Multicenter Phase II Study. J Clin Oncol. 2016;34(27):3293–3299. doi:10.1200/JCO.2016.66.446627382096
   PubMed Web of Science ®Google Scholar
• Santoro A, Mazza R, Pulsoni A, et al. Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma. Blood Advances. 2020;4(1)::136–140. doi:10.1182/bloodadvances.2019000984
   Web of Science ®Google Scholar
• Cohen JB, Wei L, Maddocks KJ, et al. Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent/refractory Hodgkin lymphoma: results of a Phase 1/2 study. Cancer. 2020;126(6):1235–1242. doi:10.1002/cncr.3264031821549
   PubMed Web of Science ®Google Scholar
• Labrador J, Cabrero-Calvo M, Pérez-López E, et al. ESHAP as salvage therapy for relapsed or refractory Hodgkin’s lymphoma. Ann Hematol. 2014;93(10):1745–1753. doi:10.1007/s00277-014-2114-024863692
   PubMed Web of Science ®Google Scholar
• Martínez C, Díaz-López A, Rodriguez-Calvillo M, et al. Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy. Br J Haematol. 2016;174(6):859–867. doi:10.1111/bjh.1413327185197
   PubMed Web of Science ®Google Scholar
• Younes A, Gopal AK, Smith SE, et al. Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin’s Lymphoma. J Clin Oncol. 2012;30(18):2183–2189. doi:10.1200/JCO.2011.38.041022454421
   PubMed Web of Science ®Google Scholar
• Chen R, Palmer JM, Martin P, et al. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2015;21(12):2136–2140. doi:10.1016/j.bbmt.2015.07.01826211987
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ, Schöder H, Yahalom J, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin’s lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015;16(3):284–292. doi:10.1016/S1470-2045(15)70013-625683846
   PubMed Web of Science ®Google Scholar
• LaCasce AS, Bociek RG, Sawas A, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018;132(1):40–48. doi:10.1182/blood-2017-11-81518329703778
   PubMed Web of Science ®Google Scholar
• O’Connor OA, Lue JK, Sawas A, et al. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin’s lymphoma: an international, multicentre, single-arm, phase 1–2 trial. Lancet Oncol. 2018;19(2):257–266. doi:10.1016/S1470-2045(17)30912-929276022
   PubMed Web of Science ®Google Scholar
• Kalac M, Lue JK, Lichtenstein E, et al. Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma. Br J Haematol. 2018;180(5):757–760. doi:10.1111/bjh.1444927984643
   PubMed Web of Science ®Google Scholar
• Picardi M, Della Pepa R, Giordano C, et al. Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma. Blood Advances. 2019;3(9):1546–1552. doi:10.1182/bloodadvances.201900012331088808
   PubMed Web of Science ®Google Scholar
• Broccoli A, Argnani L, Botto B, et al. First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi. Blood Cancer Journal. 2019;9(12):100. doi:10.1038/s41408-019-0265-x31827067
   PubMed Web of Science ®Google Scholar
• Iannitto E, Romano A, Scalzulli PR, et al. Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective real-world study. Eur J Haematol. 2020:27. doi:10.1111/ejh.13400
   Web of Science ®Google Scholar
• Abuelgasim KA, Alzahrani M, Alsharhan Y, et al. Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma. Bone Marrow Transplantation. 2019;54(7):1168–1172. doi:10.1038/s41409-019-0454-z30700792
   PubMed Web of Science ®Google Scholar
• Hagenbeek A, Mooij H, Zijlstra J, et al. Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: the HOVON/LLPC Transplant BRaVE study. Haematologica. 2019;104(4):e151–e153. doi:10.3324/haematol.2018.19689930381303
   PubMed Web of Science ®Google Scholar
• Garcia-Sanz R, Sureda A, de la Cruz F, et al. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group). Ann Oncol. 2019;30(4):612–620. doi:10.1093/annonc/mdz00930657848
   PubMed Web of Science ®Google Scholar
• Michallet A-S, Guillermin Y, Deau B, et al. Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma. Haematologica. 2015;100(7):e269–271. doi:10.3324/haematol.2015.12478425840598
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–586. doi:10.1200/JCO.2006.09.240317242396
   PubMed Web of Science ®Google Scholar
• Younes A, Hilden P, Coiffier B, et al. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol. 2017;28(7):1436–1447. doi:10.1093/annonc/mdx09728379322
   PubMed Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–3068. doi:10.1200/JCO.2013.54.880025113753
   PubMed Web of Science ®Google Scholar
• Eyre TA, Phillips EH, Linton KM, et al. Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting. Br J Haematol. 2017;179(3):471–479. doi:10.1111/bjh.1489828857136
   PubMed Web of Science ®Google Scholar
• Villa D, Seshadri T, Puig N, et al. Second-line salvage chemotherapy for transplant-eligible patients with Hodgkin’s lymphoma resistant to platinum-containing first-line salvage chemotherapy. Haematologica. 2012;97(5):751–757. doi:10.3324/haematol.2011.04767022180434
   PubMed Web of Science ®Google Scholar
• Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin’s Lymphoma. N Engl J Med. 2015;372(4):311–319. doi:10.1056/NEJMoa141108725482239
   PubMed Web of Science ®Google Scholar
• Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17(9):1283–1294. doi:10.1016/S1470-2045(16)30167-X27451390
   PubMed Web of Science ®Google Scholar
• Armand P, Engert A, Younes A, et al. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J Clin Oncol. 2018;36(14):1428–1439. doi:10.1200/JCO.2017.76.079329584546
   PubMed Web of Science ®Google Scholar
• Bair SM, Strelec LE, Feldman TA, et al. Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis. The Oncologist. 2019;24(7):955–962. doi:10.1634/theoncologist.2018-053830568021
   PubMed Web of Science ®Google Scholar
• Manson G, Mear JB, Herbaux C, et al. Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation. Eur J Cancer. 2019;115:47–56.31082693
   PubMed Web of Science ®Google Scholar
• Beköz H, Karadurmuş N, Paydaş S, et al. Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience. Ann Oncol. 2017;28(10):2496–2502. doi:10.1093/annonc/mdx34128961828
   PubMed Web of Science ®Google Scholar
• Herrera AF, Moskowitz AJ, Bartlett NL, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2018;131(11):1183–1194. doi:10.1182/blood-2017-10-81122429229594
   PubMed Web of Science ®Google Scholar
• Goldkuhle M, Dimaki M, Gartlehner G, et al. Nivolumab for adults with Hodgkin’s lymphoma (a rapid review using the software RobotReviewer). Cochrane Database Syst Rev. 2018;7:CD012556. doi:10.1002/14651858.CD01255630001476
   PubMed Web of Science ®Google Scholar
• Chen R, Zinzani PL, Lee HJ, et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood. 2019;134(14):1144–1153. doi:10.1182/blood.201900032431409671
   PubMed Web of Science ®Google Scholar
• Shi Y, Su H, Song Y, et al. Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2019;6(1):e12–e19. doi:10.1016/S2352-3026(18)30192-330612710
   PubMed Web of Science ®Google Scholar
• Johnson P, Federico M, Kirkwood A, et al. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma. N Engl J Med. 2016;374(25):2419–2429. doi:10.1056/NEJMoa151009327332902
   PubMed Web of Science ®Google Scholar
• Press OW, Li H, Schöder H, et al. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose–Positron Emission Tomography Imaging: southwest Oncology Group S0816. J Clin Oncol. 2016;34(17):2020–2027. doi:10.1200/JCO.2015.63.111927069074
   PubMed Web of Science ®Google Scholar
• Borchmann P, Goergen H, Kobe C, et al. PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised Phase 3 trial by the German Hodgkin Study Group. Lancet. 2017;390(10114):2790–2802. doi:10.1016/S0140-6736(17)32134-729061295
   PubMed Web of Science ®Google Scholar
• Schot BW, Zijlstra JM, Sluiter WJ, et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood. 2007;109(2):486–491. doi:10.1182/blood-2005-11-00695717003382
   PubMed Web of Science ®Google Scholar
• Filmont J-E, Gisselbrecht C, Cuenca X, et al. The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation. Cancer. 2007;110(6):1361–1369. doi:10.1002/cncr.2291117623832
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ, Yahalom J, Kewalramani T, et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood. 2010;116(23):4934–4937. doi:10.1182/blood-2010-05-28275620733154
   PubMed Web of Science ®Google Scholar
• Castagna L, Bramanti S, Balzarotti M, et al. Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy. Br J Haematol. 2009;145(3):369–372. doi:10.1111/j.1365-2141.2009.07645.x19344403
   PubMed Web of Science ®Google Scholar
• Chen A, Mokrane FZ, Schwartz L, et al. Early 18F-FDG PET/CT response predicts survival in Relapsed/Refractory Hodgkin Lymphoma treated with Nivolumab. J Nucl Med. 2019;119:232827. doi:10.2967/jnumed.119.232827
   Web of Science ®Google Scholar
• Spina V, Bruscaggin A, Cuccaro A, et al. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. Blood. 2018;131(22):2413–2425.29449275
   PubMed Web of Science ®Google Scholar
• Plattel WJ, Visser L, Diepstra A, et al. Interim thymus and activation regulated chemokine versus interim 18 F-fluorodeoxyglucose positron-emission tomography in classical Hodgkin lymphoma response evaluation. Br J Haematol. 2020:27. doi:10.1111/bjh.1651432420611
   PubMed Web of Science ®Google Scholar
• Venkataraman G, Mirza MK, Eichenauer DA, Diehl V. Current status of prognostication in classical Hodgkin lymphoma. Br J Haematol. 2014;165(3):287–299. doi:10.1111/bjh.1275924494650
   PubMed Web of Science ®Google Scholar
• Kamper P, Ludvigsen M, Bendix K, et al. Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma. Blood. 2011;117(24):6638–6649. doi:10.1182/blood-2010-12-32734621505194
   PubMed Web of Science ®Google Scholar
• Harrison SJ, Hsu AK, Neeson P, et al. Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant. Leuk Lymphoma. 2014;55(5):1053–1060. doi:10.3109/10428194.2013.82028723822537
   PubMed Web of Science ®Google Scholar
• Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet. 1993;341(8852):1051–1054.8096958
   PubMed Web of Science ®Google Scholar
• Schmitz N, Pfistner B, Sextro M. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359(9323):2065–2071. doi:10.1016/S0140-6736(02)08938-912086759
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Walewski J, Nademanee A, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132(25):2639–2642. doi:10.1182/blood-2018-07-86164130266774
   PubMed Web of Science ®Google Scholar
• Armand P, Chen Y-B, Redd RA, et al. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood. 2019;134(1):22–29. doi:10.1182/blood.201900021530952672
   PubMed Web of Science ®Google Scholar
• Aldinucci D, Gloghini A, Pinto A, De Filippi R, Carbone A. The classical Hodgkin’s lymphoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol. 2010;221(3):248–263. doi:10.1002/path.271120527019
   PubMed Web of Science ®Google Scholar
• Carbone A, Gloghini A, Castagna L, Santoro A, Carlo-Stella C. Primary refractory and early-relapsed Hodgkin’s lymphoma: strategies for therapeutic targeting based on the tumour microenvironment. J Pathol. 2015;237(1):4–13. doi:10.1002/path.455825953622
   PubMed Web of Science ®Google Scholar
• Passweg JR, Baldomero H, Chabannon C, et al. The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T’s come into focus. Bone Marrow Transplantation. 2020;55(8):1604–1613. doi:10.1038/s41409-020-0826-432066864
   PubMed Web of Science ®Google Scholar
• Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363(22):2091–2101. doi:10.1056/NEJMoa100438321105791
   PubMed Web of Science ®Google Scholar
• Sureda A, Canals C, Arranz R, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin’s lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2012;97:310–317.21993674
   PubMed Web of Science ®Google Scholar
• Luznik L, O’Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641–650. doi:10.1016/j.bbmt.2008.03.00518489989
   PubMed Web of Science ®Google Scholar
• Mariotti J, Devillier R, Bramanti S, et al. Peripheral Blood Stem Cells versus Bone Marrow for T Cell–Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2019;25(9):1810–1817. doi:10.1016/j.bbmt.2019.05.01731128326
   PubMed Web of Science ®Google Scholar
• Ahmed S, Kanakry JA, Ahn KW, et al. Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide–Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2019;25(9):1859–1868. doi:10.1016/j.bbmt.2019.05.02531132455
   PubMed Web of Science ®Google Scholar
• Merryman RW, Kim HT, Zinzani PL, et al. Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Blood. 2017;129(10):1380–1388. doi:10.1182/blood-2016-09-73838528073785
   PubMed Web of Science ®Google Scholar
• Schoch LK, Cooke KR, Wagner-Johnston ND, et al. Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide. Blood Advances. 2018;2(17):2226–2229. doi:10.1182/bloodadvances.201801920830190282
   PubMed Web of Science ®Google Scholar
• De Philippis C, Legrand-Izadifar F, Bramanti S, et al. Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma. Blood Advances. 2020;4(7):1242–1249. doi:10.1182/bloodadvances.201900133632227210
   PubMed Web of Science ®Google Scholar
• Robinson SP, Goldstone AH, Mackinnon S, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood. 2002;100(13):4310–4316. doi:10.1182/blood-2001-11-010712393626
   PubMed Web of Science ®Google Scholar
• Lohri A, Barnett M, Fairey RN, et al. Outcome of treatment of first relapse of Hodgkin’s disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1988. Blood. 1991;77(10):2292–2298. doi:10.1182/blood.V77.10.2292.22921709382
   PubMed Web of Science ®Google Scholar
• Reece DE, Connors JM, Spinelli JJ, et al. Intensive therapy with cyclophosphamide, carmustine, etoposide ± cisplatin, and autologous bone marrow transplantation for Hodgkin’s disease in first relapse after combination chemotherapy [see comments]. Blood. 1994;83(5):1193–1199. doi:10.1182/blood.V83.5.1193.11938118023
   PubMed Web of Science ®Google Scholar
• Brice P, Bouabdallah R, Moreau P, et al. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin’s disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle. Bone Marrow Transplantation. 1997;20(1):21–26. doi:10.1038/sj.bmt.17008389232251
   PubMed Web of Science ®Google Scholar
• Horning SJ, Chao NJ, Negrin RS, et al. High-Dose Therapy and Autologous Hematopoietic Progenitor Cell Transplantation for Recurrent or Refractory Hodgkin’s Disease: analysis of the Stanford University Results and Prognostic Indices. Blood. 1997;89(3):801–813. doi:10.1182/blood.V89.3.8019028311
   PubMed Web of Science ®Google Scholar
• Josting A, Franklin J, May M, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin’s lymphoma registered in the database of the German Hodgkin’s lymphoma study group. J Clin Oncol. 2002;20(1):221–230.11773173
   PubMed Web of Science ®Google Scholar
• Spaepen K, Stroobants S, Verhoef G, Mortelmans L. Positron emission tomography with [18F]FDG for therapy response monitoring in lymphoma patients. Eur J Nucl Med Mol Imaging. 2003;30(Suppl S1):S97–105. doi:10.1007/s00259-003-1166-512709831
   PubMed Web of Science ®Google Scholar
• Jabbour E, Hosing C, Ayers G, et al. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer. 2007;109(12):2481–2489. doi:10.1002/cncr.2271417497648
   PubMed Web of Science ®Google Scholar
• André M, Henry-Amar M, Pico JL, et al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin’s disease induction failure: a case-control study. Société Francaise de Greffe de Moelle. J Clin Oncol. 1999;17(1):222–229.10458237
   PubMed Web of Science ®Google Scholar
• Sweetenham JW, Carella AM, Taghipour G, et al. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin’s disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party. J Clin Oncol. 1999;17(10):3101–3109.10506605
   PubMed Web of Science ®Google Scholar
• Josting A, Rueffer U, Franklin J, Sieber M, Diehl V, Engert A. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood. 2000;96(4):1280–1286. doi:10.1182/blood.V96.4.128010942369
   PubMed Web of Science ®Google Scholar
• Constans M, Sureda A, Terol MJ, et al. Autologous stem cell transplantation for primary refractory Hodgkin’s disease: results and clinical variables affecting outcome. Ann Oncol. 2003;14(5):745–751. doi:10.1093/annonc/mdg20612702529
   PubMed Web of Science ®Google Scholar
• Czyz J, Szydlo R, Knopinska-Posluszny W, et al. Treatment for primary refractory Hodgkin’s disease: a comparison of high-dose chemotherapy followed by ASCT with conventional therapy. Bone Marrow Transplantation. 2004;33(12):1225–1229. doi:10.1038/sj.bmt.170450815094747
   PubMed Web of Science ®Google Scholar
• Aparicio J, Segura A, Garcerá S, et al. ESHAP is an active regimen for relapsing Hodgkin’s disease. Ann Oncol. 1999;10(5):593–595. doi:10.1023/A:102645483134010416011
   PubMed Web of Science ®Google Scholar
• Fermé C, Bastion Y, Lepage E, et al. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin’s disease. Ann Oncol. 1995;6(6):543–549. doi:10.1093/oxfordjournals.annonc.a0592428573532
   PubMed Web of Science ®Google Scholar
• Proctor SJ, Jackson GH, Lennard A, et al. Strategic approach to the management of Hodgkin’s disease incorporating salvage therapy with high-dose ifosfamide, etoposide and epirubicin: a Northern Region Lymphoma Group study (UK). Ann Oncol. 2003;14(Suppl 1):i47–50. doi:10.1093/annonc/mdg71012736232
   PubMed Web of Science ®Google Scholar
• Rothe A, Sasse S, Goergen H, et al. Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience. Blood. 2012;120(7):1470–1472. doi:10.1182/blood-2012-05-43091822786877
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Viviani S, Anastasia A, et al. Brentuximab vedotin in relapsed/refractory Hodgkin’s lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. Haematologica. 2013;98(8):1232–1236. doi:10.3324/haematol.2012.08304823645687
   PubMed Web of Science ®Google Scholar
• Gibb A, Jones C, Bloor A, et al. Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. Haematologica. 2013;98(4):611–614. doi:10.3324/haematol.2012.06939323065511
   PubMed Web of Science ®Google Scholar
• Perrot A, Monjanel H, Bouabdallah R, et al. Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30 + Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program. Haematologica. 2016;101(4):466–473. doi:10.3324/haematol.2015.13421326768687
   PubMed Web of Science ®Google Scholar
• Peggs KS, Hunter A, Chopra R, et al. Clinical evidence of a graft-versus-Hodgkin’s-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet. 2005;365(9475):1934–1941.15936420
   PubMed Web of Science ®Google Scholar
• Alvarez I, Sureda A, Caballero MD, et al. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol. Biol Blood Marrow Transplant. 2006;12(2):172–183.16443515
   PubMed Web of Science ®Google Scholar
• Corradini P, Dodero A, Farina L, et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia. 2007;21(11):2316–2323.17597807
   PubMed Web of Science ®Google Scholar
• Anderlini P, Saliba R, Acholonu S, et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin’s lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica. 2008;93(2):257–264.18223284
   PubMed Web of Science ®Google Scholar
• Devetten MP, Hari PN, Carreras J, et al. Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2009;15(1):109–117.19135949
   PubMed Web of Science ®Google Scholar
• Robinson SP, Sureda A, Canals C, et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin’s lymphoma: identification of prognostic factors predicting outcome. Haematologica. 2009;94(2):230–238.19066328
   PubMed Web of Science ®Google Scholar
• Sureda A, Canals C, Arranz R, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin’s lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2012;97(2):310–317.21993674
   PubMed Web of Science ®Google Scholar
• Kanate AS, Mussetti A, Kharfan-Dabaja MA, et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood. 2016;127(7):938–947.26670632
   PubMed Web of Science ®Google Scholar
• Ghosh N, Karmali R, Rocha V, et al. Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis. J Clin Oncol. 2016;34(26):3141–3149.27269951
   PubMed Web of Science ®Google Scholar
• Anderlini P, Saliba RM, Ledesma C, et al. Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2016;22(7):1333–1337. doi:10.1016/j.bbmt.2016.03.02827064056
   PubMed Web of Science ®Google Scholar
• Martínez C, Gayoso J, Canals C, et al. Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. J Clin Oncol. 2017;35(30):3425–3432.28846465
   PubMed Web of Science ®Google Scholar
• Gauthier J, Poiré X, Gac A-C, et al. Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin’s lymphoma undergoing allogeneic haematopoietic cell transplantation—a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. Bone Marrow Transplantation. 2018;53(4):400–409. doi:10.1038/s41409-017-0018-z29330405
   PubMed Web of Science ®Google Scholar
• Burroughs LM, O’Donnell PV, Sandmaier BM, et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008;14(11):1279–1287. doi:10.1016/j.bbmt.2008.08.01418940683
   PubMed Web of Science ®Google Scholar
• Raiola A, Dominietto A, Varaldo R, et al. Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin’s lymphoma. Bone Marrow Transplantation. 2014;49(2):190–194. doi:10.1038/bmt.2013.16624185585
   PubMed Web of Science ®Google Scholar
• Gayoso J, Balsalobre P, Pascual MJ, et al. Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: spanish multicenter experience. Bone Marrow Transplantation. 2016;51(10):1307–1312. doi:10.1038/bmt.2016.11527159177
   PubMed Web of Science ®Google Scholar
• Castagna L, Bramanti S, Devillier R, et al. Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma. Bone Marrow Transplantation. 2017;52(5):683–688. doi:10.1038/bmt.2016.34828092347
   PubMed Web of Science ®Google Scholar
• Gauthier J, Castagna L, Garnier F, et al. Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy. Bone Marrow Transplantation. 2017;52(5):689–696. doi:10.1038/bmt.2016.34928067872
   PubMed Web of Science ®Google Scholar
• Marani C, Raiola AM, Morbelli S, et al. Haploidentical Transplants with Post-Transplant Cyclophosphamide for Relapsed or Refractory Hodgkin Lymphoma: the Role of Comorbidity Index and Pretransplant Positron Emission Tomography. Biol Blood Marrow Transplant. 2018;24(12):2501–2508. doi:10.1016/j.bbmt.2018.07.02530041010
   PubMed Web of Science ®Google Scholar